Overview of treatment success with short, long, and BPaL/M regimens in patients with drug resistant tuberculosis
Abstract
Background: Drug-resistant tuberculosis (DR-TB) remains a major challenge in global TB control efforts, particularly in middle-income countries such as Indonesia. Long-term regimens lasting 18–24 months have been associated with low treatment success rates due to their prolonged duration and high incidence of adverse drug reactions. More recent developments, namely the bedaquiline–pretomanid–linezolid regimen with or without moxifloxacin (BPaL/M), have demonstrated treatment success rates of up to 89–90% in international clinical trials.
Purpose: To describe the treatment success of short-term, long-term, and BPaL/M regimens among patients with drug-resistant tuberculosis.
Method: A retrospective descriptive study was conducted using medical record data of DR-TB patients who received long-term, short-term, or BPaL/M regimens during 2023–2024. Treatment outcome classification followed the WHO 2022 guidelines. The variables collected included patient characteristics, type of regimen, and treatment outcomes based on WHO standards: cured, treatment completed, treatment failed, lost to follow-up, and died.
Results: Of the 148 DR-TB patients who met the inclusion criteria, 98 patients (66.2%) received long-term regimens, 17 patients (11.5%) received short-term regimens, and 33 patients (22.3%) were treated with the BPaL/M regimen. The treatment success rate (cured + treatment completed) for the short-term regimen was 76.5%, which was lower compared to the long-term regimen at…
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.